跳至主要内容
临床试验/CTRI/2018/10/015994
CTRI/2018/10/015994招募中3 期

Early stoppage of empirical antibiotic therapy at clinical improvement in pediatric cancer patients with high risk febrile neutropenia â?? A randomized open label clinical trial

Department Of Medical Oncology Aiims0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age 2-18 years
  • 2.AML and ALL Induction and re-induction with febrile neutropenia
  • 3.Blood culture taken prior or within 24 hrs of start of anti-microbial therapy
  • 4.Giving consent

排除标准

  • 1.Already enrolled once in previous episode
  • 2.Retroviral positive patients
  • 3.Patients who required therapeutic anti-fungals during febrile neutropenia
  • 4.Patients who required more than first line(cefoperazone-sulbactam+amikacin, levofloxacin or any oral antibiotics) and second line antibiotics(cefoperazone-sulbactam+meropenem/imipenem+teicoplanin/clindamycin)
  • 5.Patients who required inotropic support/mechanical ventilation during treatment course for febrile neutropenia
  • 6.Severe renal function impairment (defined as creatinine clearance below 30 ml/ min)
  • 7.Clinical or microbiological or radiologic focus of infection
  • 8.Patient undergone stem cell transplant

研究者

发起方
Department Of Medical Oncology Aiims

相似试验

Stoppage of antibiotics at clinical improvement in... | 临床试验